Please login to the form below

Not currently logged in
Email:
Password:

Listeria-based vaccine could halt breast cancer

Researchers in conjunction with US-based biotechnology company Advaxis develop Listeria-derived vaccines which could halt or even reverse breast cancer

Researchers from the University of Pennsylvania in conjunction with US-based biotechnology company, Advaxis, have developed of a series of cancer-fighting vaccines which may halt or even reverse breast cancer.

The vaccine was developed from investigations into the Listeria monocytogenes bacterium which grows in milk, cheese and other dairy products. The micro-organism creates a strong immune response to the presence of cancer cells.

Yvonne Paterson, professor of microbiology at the University of Pennsylvania and scientific director at Advaxis, presented evidence of the cancer-fighting properties of live, modified Listeria-based vaccines, which eradicated several types of rapidly growing cancers in mice studies.

Listeria blocks the immune system's response when it gains access to the body, helping it to spread. Researchers observed a mechanism whereby the organism directed the immune response to attack cancer cells. As a result, the vaccines taught the immune system to mount a specialised, targeted response lethal to cancer cells.

Advaxis is now preparing for clinical trials of Lovaxin B, which is aimed at treating women with pre-existing breast cancer.

Professor John Rothman, vice-president of clinical development at Advaxis, said: "While it may be a few years before we complete the studies, the promise of a cancer vaccine is truly a milestone that we hope may be attainable."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics